The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: -0.35 (-4.19%)
Spread: 0.50 (6.25%)
Open: 8.35
High: 8.00
Low: 8.00
Prev. Close: 8.35
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re. Belluscura IPO

16 Nov 2017 08:00

RNS Number : 6455W
Tekcapital plc
16 November 2017
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

16 November 2017

 

Tekcapital plc

("Tekcapital" or the "Company")

 

Update re. Belluscura IPO

The Board of Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property investment services, is delighted to note the Schedule One announcement (the "Schedule One Announcement") and the Intention to Float announcement (the "Intention to Float Announcement") released today on behalf of Belluscura Limited ("Belluscura"), in connection with the proposed admission of Belluscura's ordinary shares to trading on AIM in conjunction with a placing of new ordinary shares to raise funds (the "Belluscura IPO").

 

The Schedule One Announcement states that the admission of Belluscura's ordinary shares to trading on AIM ("Admission") is expected to take place in December 2017. The Intention to Float Announcement indicates that Belluscura is seeking to raise £7.5 million to £10 million in the placing. Belluscura's anticipated market capitalisation on Admission is yet to be confirmed. Tekcapital currently owns 47.5% in Belluscura, which at 31 May 2017 had a carrying value in Tekcapital's unaudited balance sheet of US$3,676,123. Although Tekcapital's stake in Belluscura will be diluted by the Belluscura IPO, Tekcapital anticipates the value of its stake may increase as a result.

 

The Intention to Float Announcement notes that Belluscura has recently entered into a conditional agreement to acquire from Stryker Corporation the licenses to manufacture and sell the STIC™, a hand held pressure monitor for the measurement of compartment pressure, a standard of care product line which generated average annual sales of approximately $4 million between 2011 and 2016.

 

As noted in previous Tekcapital announcements, Belluscura has previously acquired licenses to manufacture and sell four medical device product lines from Stryker, a Fortune 500 New York Stock Exchange listed medical technology company, namely the SNAPII™, the Passport®, the Slyde™ and the Wire Caddy™. Belluscura has also previously entered into a co-exclusive license and development agreement with Separation Design Group LLC to complete the development of CURV™, a portable oxygen concentrator, used to deliver concentrated oxygen to a patient requiring oxygen therapy.

 

It is anticipated that a restructuring of Belluscura's board of directors will take place in connection with the Belluscura IPO. Harry Hyman will become Belluscura's Non-Executive Chairman and Anthony Francis Martin will be Non-Executive Director. Robert Rauker and Michael Van Hoy will continue to perform the roles of Chief Executive Officer and Chief Technical Officer respectively and have been joined by Anthony Dyer, who will perform the role of Chief Financial Officer.

 

Tekcapital will make further announcements in respect of the Belluscura IPO process in due course.

 

 

For further information, please contact:

 

Tekcapital Plc

 

Clifford M. Gross, Ph.D.

info@tekcapital.com

 

Allenby Capital Limited (AIM Nominated

Adviser & Joint Broker)

 

+44 (0) 20 3328 5656

Jeremy Porter / Alex Brearley

 

 

 

Dowgate Capital Stockbrokers (Joint Broker)

+44 (0) 1293 517744

David Poutney / James Serjeant

 

 

 

Walbrook PR Ltd

+44 (0) 20 7933 8780

Paul Cornelius / Helen Cresswell / Sam Allen

tekcapital@walbrookpr.com

 

 

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties and produce returns through capital appreciation. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital makes it easy to find and acquire the new IP needed to create a competitive advantage. Our IP services include invention discovery reports, search tools, analytics and IP professional recruitment to help universities and companies create value from new discoveries. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

 

LEI: 213800GOJTOV19FIFZ85

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDEAEFSFADXFAF
Date   Source Headline
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
19th Oct 20218:00 amRNSLucyd Proposed IPO in the United States
19th Oct 20217:00 amRNSLucyd Update
14th Oct 202111:05 amRNSSecond Price Monitoring Extn
14th Oct 202111:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSSalarius FDA Sodium Reduction Goals
8th Oct 20218:59 amRNSSaltMe Roll out in leading US Supermarket Chain
29th Sep 20212:17 pmRNSLucyd Distribution Growth
20th Sep 20214:41 pmRNSSecond Price Monitoring Extn
20th Sep 20214:36 pmRNSPrice Monitoring Extension
10th Sep 202111:30 amRNSNotification of Major Shareholding
31st Aug 20217:00 amRNSLucyd Update
24th Aug 20217:00 amRNSLucyd Non Executive Director Appointment
20th Aug 20219:05 amRNSSecond Price Monitoring Extn
20th Aug 20219:00 amRNSPrice Monitoring Extension
16th Aug 20217:00 amRNSRecord Half Year Results for period to 31 May 2021
5th Aug 20212:59 pmRNSHolding(s) in Company
5th Aug 20211:44 pmRNSNotification of Major Holding
5th Aug 20217:00 amRNSLucyd Appoints Non Executive Director
22nd Jul 20217:00 amRNSLucyd launches Crowdfund
5th Jul 202112:37 pmRNSNotification of Major Holdings
5th Jul 20217:00 amRNSLucyd Signs Canadian Distribution Agreement
1st Jul 20217:00 amRNSNotification of Investor Presentation
15th Jun 20212:05 pmRNSSecond Price Monitoring Extn
15th Jun 20212:00 pmRNSPrice Monitoring Extension
15th Jun 20217:00 amRNSGrant of Share Options
8th Jun 20217:00 amRNSNotice of Investor Presentation 8 June 2021
28th May 202110:40 amRNSResults of Annual General Meeting
28th May 20217:12 amRNSBelluscura First Day of Dealings on AIM
13th May 20217:00 amRNSNotice of AGM
10th May 20217:00 amRNSInvestor Presentation
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20217:15 amRNSBelluscura Intention to Float on AIM
5th May 20217:00 amRNSPortfolio Company Update - Lucyd
4th May 20217:00 amRNSPortfolio Company Update - Guident
30th Apr 20217:00 amRNSFinal Results
1st Apr 20217:00 amRNSPortfolio Company Lucyd Update
31st Mar 20217:00 amRNSTotal Voting Rights
25th Mar 20217:00 amRNSNotification of Major Holdings
22nd Mar 20211:43 pmRNSNotification of Major Holdings
22nd Mar 20217:00 amRNSLucyd Signs Distribution Agreement
19th Mar 20214:21 pmRNSNotification of Major Holdings
19th Mar 202112:36 pmRNSNotification of Major Holdings
18th Mar 20219:05 amRNSSecond Price Monitoring Extn
18th Mar 20219:00 amRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSPlacing to raise £3.8 million
11th Mar 20217:00 amRNSSalarius update
8th Mar 20217:00 amRNSBelluscura FDA Clearance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.